Evidence map›Paper›PMID 30046420›Full record

ArticleFrontline gastroenterology2018

Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the 'intelligent LFT' pathway for the automated assessment of deranged liver enzymes.

Michael Hugh Miller, Andrew Fraser, Gillian Leggett, Alastair MacGilchrist, George Gibson, James Orr, Ewan H Forrest, Ellie Dow, William Bartlett, Chirstopher Weatherburn and 5 more

Abstract read
In one paragraph

Article in Frontline gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Multiple symptoms, multiple systems.Frontline gastroenterology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael Hugh MillerGut Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Andrew FraserNHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK.
Gillian LeggettNHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK.
Alastair MacGilchristNHS Lothian, Royal Infirmary of Edinburgh, Edinburgh, UK.
George GibsonNHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, UK.
James OrrNHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, UK.
Ewan H ForrestNHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, UK.
Ellie DowNHS Tayside, Ninewells Hospital and Medical School, Dundee, UK.
William BartlettNHS Tayside, Ninewells Hospital and Medical School, Dundee, UK.
Chirstopher WeatherburnNHS Tayside, Ninewells Hospital and Medical School, Dundee, UK.
Axel LaurellGut Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Kirsty GrantGut Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Kathryn ScottDepartment of Gastroenterology, University of Dundee, Dundee, UK.
Ronald NevilleNHS Tayside, Ninewells Hospital and Medical School, Dundee, UK.
John F DillonGut Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.

Funding

Chief Scientist Office CZH/4/1090
6 · The paper itself

Abstract

backgroundLiver function tests (LFTs) are commonly abnormal; most patients with 'incidental' abnormal LFTs are not investigated appropriately and for those who are, current care pathways are geared to find an explanation for the abnormality by a lengthy process of investigation and exclusion, with costs to the patient and to the health service.

objectiveTo validate an intelligent automatable analysis tool (iLFT) for abnormal liver enzymes, which diagnoses common liver conditions, provides fibrosis stage and recommends management.

designA retrospective case note review from three tertiary referral liver centres, with application of the iLFT algorithm and comparison with the clinician's final opinion as gold standard.

resultsThe iLFT algorithm in 91.3% of cases would have correctly recommended referral or management in primary care. In the majority of the rest of the cases, iLFT failed safe and recommended referral even when the final clinical diagnosis could have been managed in primary care. Diagnostic accuracy was achieved in 82.4% of cases, consistent with the fail-safe design of the algorithm. Two cases would have remained in primary care as per the algorithm outcome, however on clinical review had features of advanced fibrosis.

conclusioniLFT analysis of abnormal liver enzymes offers a safe and robust method of risk stratifying patients to the most appropriate care pathway as well as providing reliable diagnostic information based on a single blood draw, without repeated contacts with health services. Offers the possibility of high quality investigation and diagnosis to all patients rather than a tiny minority.

Indexed as

liver function test

Identifiers

PMID30046420
PMCPMC6056084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.